Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
This quality improvement study uses data from the MedSafer trial to evaluate drug-drug interactions between nirmatrelvir-ritonavir and maintenance medications to identify use of potentially inappropriate medications in older adults with polypharmacy.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9260479 | PMC |
| http://dx.doi.org/10.1001/jamanetworkopen.2022.20184 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Implementation of the COVID-19 antiviral therapy Nirmatrelvir/Ritonavir (Paxlovid) across Canada in 2022: A qualitative analysis of key facilitating factors and challenges.
Can Commun Dis Rep
August 2025
Public Health Agency of Canada, Montréal, QC.
Background: The COVID-19 antiviral Nirmatrelvir/Ritonavir (Paxlovid, N/R) was approved for use in Canada in January 2022, with the Government of Canada assuming a procurement role and provinces, territories, and federal departments implementing usage within their respective healthcare systems. The objective of this analysis is to describe how N/R was implemented across various jurisdictions in the first six months after it was available for use and identify promising implementation practices.
Methods: Fourteen semi-structured discussions in small group settings were conducted with jurisdictional representatives involved in the implementation of N/R.
Real-World Analysis of Potential Drug-Drug Interactions with Nirmatrelvir/Ritonavir Based on the Hospital Prescription Analysis (HPA) Database in 9 Cities of China.
Infect Drug Resist
August 2025
Department of Pharmacy, Beijing Friendship Hospital, Capital Medical University, Beijing, People's Republic of China.
Purpose: To determine the real-world patterns and extent of potential drug-drug interactions (DDIs) related to nirmatrelvir/ritonavir (NMVr) in China.
Patients And Methods: Data on NMVr-treated patients from over 160 hospitals across 9 Chinese cities from January 2022 to December 2023 were extracted from the Hospital Prescription Analysis (HPA) database, which was established in Beijing in 1997 to promote rational medication use in China. Grade C, D and X DDIs from the Lexicomp database were defined as clinically significant and analyzed in this study.
Plasma concentration of voriconazole under concomitant use of nirmatrelvir/ritonavir in patients with COVID-19: a multicenter retrospective study.
Front Pharmacol
August 2025
Department of Pharmacy, Shaoxing Campus, Sir Run Run Shaw Hospital, School of Medicine, Zhejiang University, Shaoxing, China.
Background: The concomitant use of nirmatrelvir/ritonavir and voriconazole is generally contraindicated in clinical practice because of drug‒drug interactions (DDIs). However, emerging clinical data suggest that this DDI is complicated and that the concomitant use of these two drugs may be feasible.
Methods: This was a multicenter retrospective study.
Background: Nirmatrelvir/ritonavir has emerged as a crucial treatment for managing COVID-19 infections but interacts with calcineurin inhibitors. This study aims to assess the application of a standardized protocol managing this drug-drug interaction, specifically with cyclosporine, since current evidence is limited.
Methods: This retrospective study included recipients on cyclosporine undergoing therapy with nirmatrelvir/ritonavir between April 2022 and December 2023.
Physiologically Based Pharmacokinetic Modeling to Evaluate Drug-Drug Interactions of Tacrolimus With Ritonavir, a CYP3A Irreversible Inhibitor: Applications for Dosing Optimization in Transplant Patients.
Clin Pharmacol Drug Dev
July 2025
Phase I Clinical Trial Unit, The First Affiliated Hospital With Nanjing Medical University, Nanjing, China.
Immunosuppressant tacrolimus is frequently coadministered with other drugs in clinical practice. Ritonavir is a CYP3A irreversible inhibitor that is used in combination with nirmatrelvir for the treatment of COVID-19 in nirmatrelvir/ritonavir. We aimed to apply physiologically based pharmacokinetic (PBPK) modeling to investigate the dose adjustment strategy for tacrolimus during short-term coadministration with ritonavir.
View Article and Find Full Text PDF